• 1. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789
• 4. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Quinazolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazanaphthalenes Benzodiazines Quinazolines

Introduction to 4-Chloro-6-ethoxyquinazoline (CAS No. 155960-92-2)

4-Chloro-6-ethoxyquinazoline, identified by its Chemical Abstracts Service (CAS) number 155960-92-2, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the quinazoline class, a structural framework widely recognized for its biological activity and utility in drug development. The presence of both chloro and ethoxy substituents on the quinazoline core imparts unique electronic and steric properties, making it a versatile scaffold for further chemical modifications and biological evaluations.

The quinazoline scaffold is a prominent motif in medicinal chemistry, with numerous derivatives exhibiting pharmacological properties ranging from anticancer to antimicrobial effects. The specific substitution pattern in 4-Chloro-6-ethoxyquinazoline enhances its potential as a precursor in the synthesis of novel therapeutic agents. Recent advancements in computational chemistry and high-throughput screening have highlighted the quinazoline derivatives as promising candidates for addressing various diseases, including those driven by complex molecular mechanisms.

In the context of modern drug discovery, 4-Chloro-6-ethoxyquinazoline has been investigated for its potential role in modulating key biological pathways. Studies have demonstrated that quinazoline derivatives can interact with enzymes and receptors involved in cell proliferation, inflammation, and apoptosis. The chloro substituent at the 4-position and the ethoxy group at the 6-position are particularly noteworthy, as they influence the compound's solubility, metabolic stability, and binding affinity to biological targets. These features make 4-Chloro-6-ethoxyquinazoline a valuable intermediate in designing molecules with enhanced pharmacokinetic profiles.

Recent research has also explored the synthetic methodologies for preparing 4-Chloro-6-ethoxyquinazoline and its derivatives. Modern synthetic approaches leverage transition metal catalysis and asymmetric reactions to achieve high yields and enantioselectivity. For instance, palladium-catalyzed cross-coupling reactions have been employed to introduce functional groups at specific positions of the quinazoline core, enabling the generation of structurally diverse analogs. These advances in synthetic chemistry have facilitated rapid exploration of the chemical space around 4-Chloro-6-ethoxyquinazoline, accelerating the discovery of novel bioactive compounds.

The biological activity of 4-Chloro-6-ethoxyquinazoline has been evaluated through various in vitro assays. Preliminary findings suggest that this compound exhibits inhibitory effects on certain kinases, which are critical enzymes in cancer signaling pathways. Additionally, it has shown promise in modulating immune responses, making it a potential candidate for therapeutic applications in inflammatory diseases. The structural flexibility of 4-Chloro-6-ethoxyquinazoline allows for further derivatization to optimize its pharmacological properties. For example, modifications at the 3-position or 7-position could enhance binding interactions with specific targets or improve metabolic stability.

The development of novel drug candidates often involves rigorous optimization processes to improve efficacy while minimizing side effects. In this regard, 4-Chloro-6-ethoxyquinazoline serves as a key building block for generating libraries of compounds that can be screened for their biological activity. High-throughput screening (HTS) technologies have been instrumental in identifying lead compounds derived from this scaffold. By integrating HTS with structure-based drug design, researchers can rapidly prioritize candidates for further investigation.

The role of computational tools in drug discovery cannot be overstated. Molecular modeling and virtual screening have enabled researchers to predict the binding affinity of 4-Chloro-6-ethoxyquinazoline derivatives to biological targets with high accuracy. These predictions guide experimental efforts by highlighting promising molecules that warrant further validation. Additionally, machine learning algorithms have been trained on large datasets of quinazoline derivatives to identify patterns that correlate with biological activity. Such computational approaches complement traditional experimental methods and enhance the efficiency of drug development pipelines.

Future directions in the study of 4-Chloro-6-ethoxyquinazoline include exploring its potential in combination therapies. Drug resistance remains a significant challenge in treating chronic diseases such as cancer, necessitating strategies that leverage multiple mechanisms of action. Quinazoline derivatives like 4-Chloro-6-ethoxyquinazoline could be combined with other agents to enhance therapeutic outcomes. Preclinical studies are needed to evaluate synergistic effects and optimize dosing regimens.

In conclusion, 4-Chloro-6-ethoxyquinazoline (CAS No. 155960-92-2) represents a promising scaffold for developing novel pharmaceuticals. Its unique structural features and demonstrated biological activity make it a valuable intermediate in medicinal chemistry research. Advances in synthetic methodologies, computational tools, and high-throughput screening continue to drive innovation in this field. As our understanding of disease mechanisms evolves, compounds like 4-Chloro-6-ethoxyquinazoline will play an increasingly important role in addressing unmet medical needs.

• 183322-18-1(4-Chloro-6,7-bis(2-methoxyethoxy)quinazoline)
• 557770-90-8(7-(3-Chloropropoxy)-4-Chloroquinazoline)
• 1223748-36-4(4-Chloro-6-isopropoxyquinazoline,)
• 183322-21-6(4-Chloro-6,7-bis-(2-chloroethoxy)quinazoline)
• 162363-46-4(4-Chloro-6,7-diethoxyquinazoline)
• 52791-05-6(4-chloro-7H,8H-1,4dioxino2,3-gquinazoline)
• 55496-52-1(4-Chloro-7-methoxyquinazoline)
• 62484-33-7(Quinazoline, 2,4-dichloro-7-propoxy-)
• 179246-11-8(4-Chloroquinazolin-6-yl acetate)
• 50424-28-7(4-Chloro-6-methoxyquinazoline)